Cellectis (CLLS) Current Assets (2013 - 2026)
Cellectis (CLLS) posted quarterly Current Assets of $204.5 million for Q1 2026, down 24.75% year-over-year from $271.8 million in Q1 2025, and down 13.42% quarter-over-quarter from $236.2 million in Q4 2025.
Cellectis (CLLS) Current Assets (2013 - 2026) Analysis & Trends
Cellectis' Current Assets history runs 14 years deep, the most recent figure standing at $204.5 million for Q1 2026.
- In Q1 2026, Current Assets fell 24.75% year-over-year to $204.5 million; the TTM figure through Mar 2026 stood at $204.5 million (down 24.75% YoY), while the FY2025 annual figure was $236.2 million, down 17.7% from the prior year.
- Current Assets for Q1 2026 stood at $204.5 million, down from $236.2 million in the prior quarter.
- The five-year high for Current Assets was $305.8 million in Q2 2024, with the low at $96.5 million in Q3 2023.
- The 5-year median for Current Assets is $221.2 million (2025), against an average of $206.0 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets tumbled 45.86% in 2022, then soared 205.13% in 2024.
- Cellectis' Current Assets stood at $122.0 million in 2022, then soared by 90.92% to $233.0 million in 2023, then gained by 23.2% to $287.1 million in 2024, then decreased by 17.7% to $236.2 million in 2025, then declined by 13.42% to $204.5 million in 2026.
- Business Quant data shows CLLS's Current Assets at $204.5 million in Q1 2026, $236.2 million in Q4 2025, and $221.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 204.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 204.55 Mn |
| Dec 31, 2025 | 236.24 Mn |
| Sep 30, 2025 | 221.19 Mn |
| Jun 30, 2025 | 230.64 Mn |
| Mar 31, 2025 | 271.83 Mn |
| Dec 31, 2024 | 287.07 Mn |
| Sep 30, 2024 | 294.43 Mn |
| Jun 30, 2024 | 305.80 Mn |
| Mar 31, 2024 | 258.07 Mn |
| Dec 31, 2023 | 233.01 Mn |
| Sep 30, 2023 | 96.49 Mn |
| Jun 30, 2023 | 113.29 Mn |
| Mar 31, 2023 | 117.23 Mn |
| Dec 31, 2022 | 122.04 Mn |
| Sep 30, 2022 | 140.27 Mn |
| Jun 30, 2022 | 175.17 Mn |
| Mar 31, 2022 | 195.18 Mn |
| Dec 31, 2021 | 225.43 Mn |
| Sep 30, 2021 | 235.85 Mn |
| Jun 30, 2021 | 280.35 Mn |